$GDTC

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - CytoMed Therapeutics (NASDAQ:GDTC)

SINGAPORE, July 21, 2025 ( GLOBE NEWSWIRE ) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited GDTC ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to ...

Original reporting
Benzinga · Globe Newswire
Published Jul 21, 2025, 2:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2025, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - CytoMed Therapeutics (NASDAQ:GDTC) — source image
Decision brief

The 30-second read

$GDTCNeutralLow
01

Why it matters

Successful trial progression may enhance company valuation and investor confidence.

02

Market read

The news is relevant primarily to biotech investors and stakeholders interested in cancer treatment developments.

03

What to watch

Regulatory hurdles, funding requirements, and competitive landscape could influence outcome.

Timing: short-term (next 1-2 weeks)

Background

CytoMed Therapeutics is a Singapore-based biotech company focusing on cancer treatments.

Company-level read

Ticker impact

$GDTCNeutralMedium confidence
Context

Primary focus due to recent clinical trial milestone.

Expected impact

Minimal immediate impact; potential long-term positive if trial progresses successfully.

Evidence & confidence

The news confirms progress in clinical trials, which is positive but does not directly influence stock price until further milestones are achieved.

Market effects

Potential positive sentiment for biotech and clinical-stage pharmaceutical sectors.

Limited to Singapore and biotech-focused markets.

Moderate; reflects ongoing advancements in cancer therapeutics.

Counterpoint

Progress in clinical trials does not guarantee eventual market approval or commercial success.

Key entities

  • CytoMed Therapeutics Limited

    A clinical-stage biopharmaceutical company specializing in cancer therapeutics.

  • ANGELICA Trial

    A Phase 1 trial evaluating CytoMed's novel therapeutic approach.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.